Auto-generated from public data. Not the firm's stated position.
Hadean Ventures appears to focus on early-stage investments across biotech, edtech, and fintech sectors, with a demonstrated concentration in life sciences and medical technology companies. Recent portfolio activity suggests a preference for European-based founders in the pre-seed to seed stages, with typical check sizes between EUR 1.5M and EUR 3.0M. Based on disclosed data, the firm leverages its substantial AUM of approximately EUR 230M to support innovation in therapeutics and medical devices across Northern and Continental Europe.
Generated 30 Sept 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Hadean Ventures's website.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.